-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB: Invitation to Corporate Update Event
21 Sep 2020Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress
17 Sep 2020Immunicum AB (publ) Announces Publication of Abstract for the ESMO Virtual Congress 2020
14 Sep 2020
News
-
ESMO Virtual Congress 2020 Poster Presentation
17 Sep 2020 -
Get to know Dr Sven Rohmann our new CEO
15 Sep 2020 -
ESMO 2020 Virtual Congress Abstract
14 Sep 2020 -
Corporate Presentation – August 2020
18 Aug 2020 -
Article in BioStock / Immunicum gears up for second half of 2020
15 Jul 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
